Fat-Dissolving Injections Beyond Kybella: Why Deoxycholic Acid Is the Only Injectable the FDA Has Ever Approved to Destroy Fat, What Happened When Lipodissolve Tried to Skip the Trials, and Why a Product Sold as a Cosmetic Should Never Meet a Needle

Fat-dissolving injections have become a category, and the category is doing a great deal of work that only one product has earned. Deoxycholic acid, sold in the United States as Kybella, is the single injectable drug the Food and Drug Administration has ever approved to destroy fat, and it is approved for one site, the fullness beneath the chin, at a dose and a spacing written into its label. Everything else sold under the same phrase, the Aqualyx that British clinics have injected for a decade, the Lemon Bottle that ran through TikTok in 2023, the phosphatidylcholine and deoxycholate cocktails that were marketed as lipodissolve in the 2000s, shares the name and none of the evidence.

The short version, which the rest of this piece defends: an injection that destroys fat does so by rupturing cell membranes, the rupture produces inflammation whether or not it produces a result, and the difference between an approved product and an unapproved one is not the mechanism but whether anyone has measured what that inflammation does over a thousand patients. Kybella's own trials are the honest benchmark, and they show a modest, reliable effect at the chin with a side effect list that includes temporary nerve injury and skin breakdown. A product with no trials cannot be assumed to do better, and the American experience with lipodissolve is a record of what happens when the assumption is made anyway.

This piece sits alongside the piece on non-surgical double chin options, which covers where deoxycholic acid fits against cryolipolysis and radiofrequency at the chin, and the piece on non-surgical body contouring, which covers the device side of the same market. Neither is repeated here. This is about the injection itself: what it is, what it is not, and how to tell the difference when the product in the syringe has a name you have only seen in a caption.

What a fat-dissolving injection actually does, and why only one has an American approval

The short answer: the active ingredient in every product that dissolves fat is a detergent that ruptures the fat cell membrane, deoxycholic acid is that detergent in purified form, and its FDA approval in April 2015 rests on two placebo-controlled trials that no competing product has run.

The mechanism is not subtle. Deoxycholic acid is a bile acid the body makes to emulsify dietary fat in the gut, and injected into a fat pad it does the same thing to the fat cell that it does to a droplet of oil: it disrupts the lipid membrane, the cell ruptures, and the released fat and cell debris provoke an inflammatory response that clears the material over weeks. What is left is fibrosis, a small amount of new collagen where the fat was, and a measurable reduction in the thickness of the pad. The word dissolving suggests something gentler, a melting away, and the histology says otherwise: this is cell death by chemical lysis, followed by an inflammatory clean-up, and the swelling the patient feels for a week is the clean-up under way.

That the detergent was the point took a while to establish. Through the 1990s and early 2000s the injections then in circulation were sold as phosphatidylcholine, a soybean-derived lipid, with the claim that the lecithin emulsified the fat. The deoxycholate in those formulations was described as a solvent that kept the phosphatidylcholine in solution. In 2004 a group at the University of California, Los Angeles, led by Adam Rotunda and Michael Kolodney, published in Dermatologic Surgery a laboratory comparison showing that deoxycholate alone produced the same cell lysis as the full phosphatidylcholine mixture, and that the phosphatidylcholine was largely along for the ride. That finding is the origin of the purified drug. Kythera Biopharmaceuticals licensed the work, ran it through a development program under the name ATX-101, and sold the resulting company to Allergan in 2015 for roughly 2.1 billion dollars, which is a fair estimate of what a proven fat injection was thought to be worth.

The approval itself came on April 29, 2015, on the strength of two identically designed Phase 3 trials, REFINE-1 and REFINE-2, which together enrolled just over a thousand adults with moderate to severe fullness beneath the chin and randomised them to deoxycholic acid or saline. The results are worth stating plainly because they are the only numbers in this category that were collected against a placebo. Roughly seven in ten treated patients improved by at least one grade on the clinician and patient rating scales, against roughly two in ten on saline. Improvement by two grades, the larger change most patients picture, was reached by a much smaller fraction, on the order of one in six against a few percent for placebo. Magnetic resonance imaging confirmed that the fat pad had shrunk. The drug worked, and it worked modestly, and both halves of that sentence are on the label.

The label also defines the procedure in a way that every other product lacks. Injections of 0.2 millilitres are placed at one-centimetre intervals across a grid drawn on the submental fat, up to 50 injections per session, at least a month apart, for up to six sessions. The drug is approved for fat beneath the chin in adults and nowhere else. Use at the jowls, the bra line, the abdomen, the knees, and the dorsocervical hump is off label, which is legal for a licensed prescriber and unstudied at the volumes those sites require. Deoxycholic acid is a prescription drug, which means the person injecting it in the United States has to be a clinician working under a prescriber, a fact that matters enormously once the discussion moves to products that are not drugs at all.

• Mechanism: a detergent ruptures the fat cell membrane; inflammation clears the debris; fibrosis replaces some of the volume.
• The evidence: two placebo-controlled trials of just over a thousand patients, one-grade improvement in roughly 70 percent against roughly 20 percent on saline, MRI-confirmed reduction.
• The label: submental fat only, 0.2 millilitre injections on a one-centimetre grid, up to 50 per session, up to six sessions a month apart.
• The status: the only injectable fat-reduction drug with an FDA approval, and a prescription product that cannot legally be injected by a layperson.

The lipodissolve era, and how an unapproved fat injection ended in a state ban and federal warning letters

The short answer: between roughly 2003 and 2010 American clinics injected compounded phosphatidylcholine and deoxycholate mixtures under names like lipodissolve and mesotherapy with no controlled evidence, Brazil banned the practice in 2003, Kansas banned it in 2008, and in April 2010 the FDA sent warning letters to a group of clinics for marketing an unapproved drug with unsupported claims.

The story starts in Europe with a drug called Lipostabil, a phosphatidylcholine and deoxycholate solution licensed in Germany for intravenous use in fat embolism, a condition in which fat globules block blood vessels after a fracture. Brazilian dermatologists in the late 1990s began injecting it into fat pads, first under the eyes and then wherever fat was unwanted, and reported that the pads shrank. The reports were case series. There was no control group, no standard dose, and no long-term follow-up, and the Brazilian regulator, ANVISA, banned the cosmetic use of phosphatidylcholine injections in 2003 on the grounds that the manufacturer had never established safety for injection into fat. That ban was the first regulatory verdict on the category, and it came from the country that had invented the use.

The practice crossed to the United States anyway, in two forms. One was mesotherapy, a French technique dating to the 1950s in which small quantities of drugs, vitamins, and plant extracts are injected into the skin and subcutaneous fat, which American practitioners adapted into cocktails for fat reduction whose contents varied from clinic to clinic and were rarely disclosed. The other was lipodissolve, a more standardised phosphatidylcholine and deoxycholate mixture obtained from compounding pharmacies and sold through chains of medical spas with aggressive advertising, a series of sessions priced in the low thousands, and no published trial. The American Society for Aesthetic Plastic Surgery issued a statement in 2005 warning that mesotherapy for fat had no scientific support, and the American Society of Plastic Surgeons followed with position statements advising members that lipodissolve was unproven; both are on the record and both were ignored by the market for several years.

The regulators moved slowly and then all at once. In 2008 the Kansas State Board of Healing Arts prohibited the injection of lipodissolve compounds, the first state to do so, after complaints of persistent nodules, skin ulceration, and infection. In April 2010 the FDA issued warning letters to six American medical spas and one Brazilian company, stating that the phosphatidylcholine and deoxycholate products they were marketing were unapproved new drugs, that the claims of safety and effectiveness were unsupported, and that the agency was aware of reports of permanent scarring, skin deformation, and deep painful knots at the injection sites. The letters did not ban the compounds, because the FDA does not regulate the practice of medicine, but they removed the advertising, the chains folded, and the term lipodissolve disappeared from American marketing within a couple of years. What replaced it, five years later, was the purified drug that had gone through the trials the compounders had skipped.

The lesson is not that the detergent was wrong. The detergent was right; that is the whole basis of the approved product. The lesson is that the same molecule, at an undisclosed concentration, in a mixture no one had characterised, injected by staff at a chain that advertised on billboards, produced a run of injuries severe enough to draw a state ban and a federal letter, and that the people who were injured had been told the injection was well established because clinics abroad had been doing it for years. The piece on who is injecting you at a med spa covers the supervision rules that were supposed to prevent that, and the piece on illegal silicone injections covers the far worse version of the same pattern.

• Lipostabil: a German intravenous drug for fat embolism, never licensed for injection into fat.
• Brazil, 2003: ANVISA bans cosmetic phosphatidylcholine injections.
• ASAPS, 2005, and ASPS after it: formal statements that mesotherapy and lipodissolve for fat are unproven.
• Kansas, 2008: the first state prohibition on lipodissolve injection.
• FDA, April 2010: warning letters to six American clinics and one Brazilian company for marketing an unapproved drug, citing reports of permanent scarring and deep nodules.

What is in the vials being sold now: Aqualyx, the deoxycholate copies, and Lemon Bottle

The short answer: Aqualyx and its Italian relatives are deoxycholate solutions with a European device mark and no FDA approval, Lemon Bottle is a Korean product whose listed ingredients have no established fat-dissolving action and which has no controlled trial in the published literature, and none of them is legal to inject as a drug in the United States.

Aqualyx is the product a patient is most likely to have heard of if she has spent time on British or European clinic pages. It is a solution of deoxycholate in a gel carrier, made by an Italian company, and it has been sold in Europe since about 2009 under a CE mark, which is the conformity marking that allows a medical device to be sold in the European market. The distinction matters. A CE mark on a device certifies that the manufacturer has met a set of safety and quality standards; it is not an efficacy approval of the kind the FDA grants a drug, and the fact that a fat-dissolving injection was classified as a device rather than a drug in Europe is itself a regulatory choice that the FDA has never accepted. Aqualyx has published case series and small open-label studies, mostly from the manufacturer's own investigators, and no placebo-controlled trial on the scale of the deoxycholic acid program. It is, in practical terms, the same detergent as Kybella at a different concentration in a different carrier, sold on a different continent under a lighter standard of proof, and it is not approved for any use in the United States.

Beside it sit a family of similar products, Desobody and Desoface among them, that make the same claim with the same molecule and the same European mark. Where these appear in American clinics they have generally been imported outside the approved supply chain, which is the situation the piece on skin boosters and what is approved describes for an adjacent category: a European product with a plausible mechanism, a device classification, and no legal route into an American syringe.

Lemon Bottle is a different case, and a stranger one. It is a Korean product that reached international attention through short-form video in 2023, in clips showing an injector pressing on a chin or an abdomen and a fat pad apparently softening within minutes. Its listed ingredients are riboflavin, which is vitamin B2, bromelain, which is a pineapple enzyme, and lecithin, the same soybean phospholipid the lipodissolve era leaned on. None of the three has an established fat-lysing action at any dose that could be injected, bromelain is a protein-digesting enzyme with no known mechanism against a lipid membrane, and the lecithin is present without the deoxycholate that the 2004 laboratory work identified as the actual active agent. At the time of writing there is no placebo-controlled trial of Lemon Bottle in the indexed literature, and no controlled trial of any design. The manufacturer markets it as a cosmetic-grade solution rather than a drug, which is the point on which the whole product turns: a cosmetic is not authorised for injection anywhere, so an injector using it is injecting a product that no regulator has reviewed for that route, and in most American states a person who is not a licensed clinician is not permitted to inject anything at all. British aesthetic and plastic surgery bodies issued warnings to that effect in 2023 and 2024; the FDA has not approved it and has no reason to have looked at it.

The dramatic videos have an explanation that has nothing to do with fat. An injection of any fluid into a fat pad produces a wheal that spreads and flattens as the fluid disperses; massage of a swollen area moves the fluid; and a clip filmed over ten minutes shows a change in the surface that a clip filmed over ten weeks would not. The piece on influencer disclosure covers why a product that reaches patients through a caption rather than a consultation is sold on a demonstration of exactly the kind that cannot be checked, and the piece on trademarked procedure names covers why a name that sounds like a brand is often the only thing that has been registered.

"

The only difference between a fat-dissolving injection that has been approved and one that has not is whether anyone counted what happened to a thousand patients before it was sold. The detergent does not know which vial it came from.

"

• Aqualyx and the Italian deoxycholate products: the same detergent as Kybella, a European device mark, small manufacturer-linked studies, no FDA approval, no legal American supply.
• Lemon Bottle: riboflavin, bromelain, and lecithin, no established mechanism, no controlled trial, marketed as a cosmetic, not authorised for injection by any regulator.
• The video demonstrations: fluid dispersal and massage filmed over minutes, not fat loss measured over months.

What the injection does to the tissue, and why the harm is the same whether the product works or not

The short answer: every fat-dissolving injection produces inflammation, and the complications that matter, nerve injury, skin ulceration, hard nodules, and infection, come from the inflammation, the placement, and the sterility of the product rather than from whether the fat actually shrank, so an unproven product carries every risk of the approved one and adds the risk of doing nothing.

Kybella's trial data are the honest map of what to expect from a detergent in fat, because the trials recorded the harms as carefully as the benefits. Nearly every patient had swelling, bruising, pain, and numbness at the site for days to a couple of weeks after each session, and induration, a firm thickening of the treated area, that resolved over weeks to a few months. About four percent of treated patients had a temporary injury to the marginal mandibular branch of the facial nerve, which runs just above the jawline and controls the lower lip; the sign is an asymmetric smile, and in the trials it resolved in a median of about six weeks, with the longest cases taking several months. A couple of percent had difficulty swallowing for a period. Skin ulceration and necrosis occurred where the drug was placed too superficially, and the label instructs the injector to stay within the fat and away from the skin, the platysma, and the nerve. Case reports since approval add hair loss at the injection site in men, and vascular injury when the drug was used at sites near named vessels. The piece on facial nerve injury describes the marginal mandibular branch and why it is the one that trips up procedures at the jawline.

Now consider what changes with an unapproved product. The detergent, where the product has one, is at a concentration the injector cannot verify against a label. The volume per injection and the spacing are whatever the training course said, and there is no grid on the label to correct it. The product's sterility rests on a manufacturer and an import chain that no American regulator has inspected, and the infectious disease literature on mesotherapy includes clusters of nontuberculous mycobacterial infection, slow-growing abscesses that surface weeks after injection and need months of antibiotics and often surgical drainage, traced to contaminated solutions and non-sterile technique. Where the product has no detergent, as with Lemon Bottle, the patient gets the needle, the fluid, the swelling, and the infection risk, and no fat loss to show for them.

The nodules deserve their own paragraph, because they are the complaint that drove the Kansas ban and they are the one most likely to bring a patient to a plastic surgeon a year later. A detergent that lyses fat unevenly leaves islands of dead fat and inflamed tissue that scar into firm, sometimes tender lumps, and where the product is injected in larger volumes than the chin takes, at the abdomen or the flanks or the thighs, the lumps can be numerous and visible. They do not dissolve. They are treated, if at all, with steroid injection, with time, or with excision, and a patient who came in for a needle to avoid a scar can end up with the scar and the lump. The piece on delayed filler nodules covers the parallel problem in the filler world, and the piece on fat necrosis after fat transfer covers the same biology when the dead fat is the patient's own graft.

And there is the question of who is holding the syringe. Because deoxycholic acid is a prescription drug, its injection in the United States is confined to clinicians. Because Aqualyx and Lemon Bottle are not drugs on any American register, they are sold and injected through channels that a prescription product cannot reach: training courses for aestheticians, mobile injectors, and salons. The product with no evidence is therefore also, in practice, the product injected by the person with the least training and the least ability to recognise a nerve palsy, a vascular event, or a mycobacterial abscess. The piece on vascular occlusion risk with fillers explains what an injector has to be ready for when a needle goes near a vessel in the face; a detergent injected into a vessel is a variation on that emergency, not an exemption from it.

• The approved product's own harms: near-universal swelling and induration, marginal mandibular nerve weakness in about four percent, swallowing difficulty in a couple of percent, ulceration when placed superficially.
• What an unapproved product adds: unverifiable concentration, no labelled grid, uninspected sterility, mycobacterial infection clusters in the mesotherapy record, and, for products without a detergent, no effect at all.
• The nodules: uneven lysis scars into firm lumps that need steroid, time, or excision, and they are the complication that ends up in a surgeon's office.
• The injector: the products with the least evidence reach the patient through the least trained hands.

Where a fat-dissolving injection is actually the right choice, and where it is a slow, expensive way to avoid liposuction

The short answer: an approved deoxycholic acid course suits a small, discrete pocket of fat beneath the chin in a patient with good skin who would rather have three or four sessions of swelling than one operation; for a larger pocket, loose skin, or any site other than the chin, liposuction removes more fat in one visit, with a predictable result and a scar the size of a freckle, and usually for less money over the course.

Start with the arithmetic that the marketing leaves out. A single session of deoxycholic acid at the chin uses up to 10 millilitres of drug, and the drug is priced per vial; a typical course is two to four sessions, and patients with larger pads may need all six the label permits. Each session brings a week or two of visible swelling, so a four-session course is a spring of looking worse before looking better, and the total cost of a full course in most American markets lands in the same range as, and often above, submental liposuction performed once under local anaesthesia. The injection wins on the absence of a procedure room and on the patient who cannot or will not accept any incision. It does not win on total downtime, on cost, or on the amount of fat removed.

It also does nothing for skin, and skin is the reason a double chin in a patient past forty usually looks the way it does. Deoxycholic acid removes fat above the platysma and leaves the skin that covered it to contract on its own, which young skin does and older skin does not. The piece on the aging neck and platysmaplasty covers why a neck that has loose skin, muscle bands, or fat beneath the muscle is not an injection problem at all, and the piece on jawline contouring at forty separates the three changes that the word jowl usually conflates. A patient who dissolves the fat under a lax neck gets a slightly emptier lax neck.

Then there is the off-label sprawl. The same injectors who offer deoxycholic acid at the chin will offer it at the jowls, the bra roll, the knees, the abdomen, and the upper arms, and the small published series at those sites describe swelling, nodules, and modest change against a volume of fat that the drug was never dosed for. The abdomen alone can hold many times the volume of a submental pad, and the number of sessions needed to make a visible difference with 0.2 millilitre injections on a one-centimetre grid is a number no one has studied. Liposuction at those sites is a single procedure with sixty years of outcome data behind it, and the piece on liposuction versus liposculpture covers what the operation can do that no injection can, which is to shape rather than merely reduce.

The honest indication for the approved injection, then, is narrow and real: a discrete submental pad of moderate size, good skin, a patient under about forty-five or with unusually good elasticity, and a preference for needles over an incision that is strong enough to accept more sessions, more total swelling, and a comparable or higher cost. For that patient the drug works, the trials say so, and the trials are the reason it can be recommended. For every other patient, and for every product without trials, the recommendation is the operation or nothing. The piece on how the field treats deeper skin tones is worth reading before any injection at the chin, because the post-inflammatory darkening that follows a course of detergent inflammation is more likely and more lasting on darker skin, and it is a risk that neither the label nor the videos mention.

The honest summary

• One product has earned the name. Deoxycholic acid, sold as Kybella, is the only injectable the FDA has approved to destroy fat, on the basis of two placebo-controlled trials of about a thousand patients, and it is approved for the fat beneath the chin and nowhere else.
• The effect is modest and the harms are real. Roughly seven in ten treated patients improved by one grade against two in ten on saline; nearly all had swelling and induration; about four percent had a temporary weakness of the lower lip; a small number had skin breakdown.
• The unapproved products are not new. Compounded phosphatidylcholine and deoxycholate injections went through the same cycle in the 2000s, from case series abroad to billboard chains at home to a Brazilian ban, a Kansas ban, and FDA warning letters in April 2010 citing permanent scarring and deep nodules.
• Aqualyx is the same detergent under a lighter standard, and Lemon Bottle is not a detergent at all. Neither has a placebo-controlled trial, neither has an American approval, and the product sold as a cosmetic reaches the patient through the injectors with the least training.
• The choice is the approved drug at the chin or the operation everywhere else. A discrete submental pad in good skin is the one indication the evidence supports; larger pockets, loose skin, and every other site are a liposuction question, and usually a cheaper one over the course.

The phrase fat-dissolving injection is doing what such phrases always do in this field: lending the credibility of one tested product to a shelf of untested ones that share a word with it. The detergent in the approved vial and the detergent in the imported one behave identically in the tissue, which is exactly why the trials matter; they are the only thing that turned a plausible mechanism into a known result with a known cost. A patient who wants the injection should insist on the product that ran them, at the one site they covered, from the hands the law requires. A patient offered anything else has been offered the lipodissolve era with a new caption, and the ending of that story has already been written.